Kasper W, Meinertz T, Wollschläger H, Bonzel T, Wolff P, Drexler H, Hofmann T, Zeiher A, Just H
Am J Cardiol. 1986 Sep 1;58(6):418-21. doi: 10.1016/0002-9149(86)90006-8.
The safety and fibrinolytic efficacy of a new anisoylated plasminogen-streptokinase activator complex (APSAC) was tested in 50 patients with acute myocardial infarction (AMI) less than 4 hours in duration. APSAC (30 mg) was given intravenously as a bolus injection 151 +/- 47 minutes after clinical symptoms. Coronary angiography was then performed to assess coronary artery patency: 28 patients had an inferior AMI and 22 an anterior AMI. A patent infarct-related artery was found in 32 patients (64%) on first coronary angiography 66 +/- 21 minutes after administration of APSAC. Subsequent reperfusion was observed in 10 patients after 74 +/- 16 minutes (84%). Bleeding complications or hematomas were observed in 18 patients, of whom 3 required blood transfusions. Marked hypofibrinogenemia was observed within 24 hours in most patients. A control coronary angiogram was recorded in 37 patients (74%) after 25 +/- 19 days and showed reocclusion in 5 patients.
在50例病程小于4小时的急性心肌梗死（AMI）患者中测试了一种新型茴香酰化纤溶酶原-链激酶激活剂复合物（APSAC）的安全性和纤溶疗效。在出现临床症状后151±47分钟静脉推注给予APSAC（30毫克）。然后进行冠状动脉造影以评估冠状动脉通畅情况：28例为下壁AMI，22例为前壁AMI。在给予APSAC后66±21分钟进行的首次冠状动脉造影中，32例患者（64%）发现梗死相关动脉通畅。74±16分钟后在10例患者中观察到后续再灌注（84%）。18例患者观察到出血并发症或血肿，其中3例需要输血。大多数患者在24小时内出现明显的纤维蛋白原血症。37例患者（74%）在25±19天后记录了对照冠状动脉造影，5例显示再闭塞。
